Table 4.
SOAR Efficacy Outcomes (intention to treat)a.
| Outcome | Women (n = 18) |
Men (n = 12) |
||||
|---|---|---|---|---|---|---|
| Baseline (T0) Median (min-max) | End (T1) Median (min-max) | Change (T1-T0) Mean (95%CI) | Baseline (T0) Median (min-max) | End (T1) Median (min-max) | Change (T1-T0) Mean (95%CI) | |
| KOOSPaind | 83 (58–100) | 86 (47–100) | 1.3 (−3.5,6.0) | 88 (69–97) | 86 (75–100) | 2.1 (−3.3,7.5) |
| KOOSSympd | 55 (36–79) | 54 (39–75) | 1.8 (−1.7,5.3) | 57 (43–71) | 63 (43–68) | 1.2 (−4.2,6.6) |
| KOOSADLd | 98 (79–100) | 96 (53–100) | −1.6 (−8.1,4.8) | 98 (81–100) | 96 (81–100) | 0.6 (−3.4,4.6) |
| KOOSSR | 73 (45–95) | 90 (25–100) | 8.3 (−2.3,19.0) | 75 (50–100) | 75 (50–100) | 3.8 (−6.7,14.1) |
| KOOSQoL | 47 (25–81) | 56 (0–88) | 6.6 (−1.4,14.6) | 50 (25–88) | 56 (44–88) | 6.8 (−2.5,16.1) |
| KOOSPF | 74 (41–91) | 78 (27–96) | 6.3 (−1.3,14.0) | 76 (50–91) | 71 (57–96) | 1.5 (−6.2,9.2) |
| PSFSb | 5 (0–7) | 6 (2–9) | 1.7 (0.6,2.8) | 6 (3–8) | 6 (4–8) | −0.4 (−1.9,1.1) |
| PHS | 20 (5–37) | 8 (0–32) | −7 (-11,-3) | 20 (0–41) | 11 (2–30) | −5 (−13,4) |
| GLTQc | 56 (13–118) | 71 (37–224) | 22 (6,37) | 66 (23–92) | 90 (35–185) | 31 (8,54) |
T0 (Baseline), T1 (4-weeks).
Bold: mean change 95% confidence interval does not contain the null value.
a
See Supplementary File 1 for a sensitivity analysis where data from one participant who experienced a time loss knee injury in the first week of the program during a non-SOAR related event is removed.
b
Average across three goals.
c
Metabolic equivalents.
d
As per Collins et al., 2016,37 KOOS pain, symptoms and function in daily living have limited validity for this patient group and would not be expected to change.